ENLV
Enlivex Therapeutics Ltd. NASDAQ Listed Jul 31, 2014$0.59
+3.75%
vs $0.57
Mkt Cap $14.4M
52w Low $0.56
2.4% of range
52w High $2.10
50d MA $0.75
200d MA $0.95
P/E (TTM)
0.0x
EV/EBITDA
—
P/B
0.0x
Debt/Equity
0.0x
ROE
63.8%
P/FCF
-2.6x
RSI (14)
22.10
ATR (14)
$0.06
Beta
1.68
50d MA
$0.75
200d MA
$0.95
Avg Volume
406.7K
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
14 Einstein Street · Ness Ziona 7403618 · IL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.03 | -0.23 | -666.7% | 0.90 | +2.2% | +3.3% | +3.5% | -1.1% | -8.2% | -4.6% | — |
| Mar 25, 2026 | AMC | -0.09 | 27.35 | +9999.0% | 1.20 | -2.5% | -9.2% | -3.7% | -14.3% | +3.3% | +3.5% | — |
| Nov 14, 2025 | AMC | -0.12 | -0.09 | +25.0% | 0.99 | -2.1% | -1.6% | +0.3% | -4.1% | -2.8% | -1.7% | — |
| Aug 29, 2025 | AMC | -0.16 | -0.08 | +50.0% | 1.05 | -1.0% | +1.0% | +0.0% | +0.9% | -0.9% | -1.9% | — |
| May 30, 2025 | AMC | -0.16 | -0.15 | +6.2% | 0.94 | +3.6% | +0.4% | +0.0% | -1.1% | -1.1% | +5.2% | — |
| Feb 26, 2025 | AMC | -0.16 | -0.24 | -47.8% | 1.00 | +5.0% | +3.0% | +16.5% | -15.0% | +5.9% | +4.6% | — |
| Nov 29, 2024 | AMC | -0.16 | -0.12 | +25.0% | 1.14 | -2.6% | -5.3% | +20.4% | +0.0% | -6.2% | +2.5% | — |
| Aug 30, 2024 | AMC | -0.22 | -0.16 | +27.3% | 1.30 | -3.8% | -3.1% | -2.4% | +0.0% | +3.3% | -5.5% | — |
| Jun 14, 2024 | AMC | -0.25 | -0.22 | +12.0% | 1.46 | -0.7% | -4.8% | -7.2% | +2.3% | +3.0% | +3.7% | — |
| Mar 29, 2024 | AMC | -0.28 | -0.48 | -71.4% | — | — | — | — | — | — | — | — |
| Nov 9, 2023 | AMC | -0.32 | -0.32 | +0.0% | 1.75 | +0.6% | +2.3% | -2.2% | -2.3% | +2.3% | -0.6% | — |
| Sep 1, 2023 | AMC | -0.43 | -0.37 | +14.0% | 2.35 | +1.3% | -0.9% | +0.4% | -0.9% | -5.2% | -12.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.87 | $0.90 | +3.3% | -4.6% | +12.0% | +1.8% | +1.3% | -12.8% |
| Jan 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.90 | $0.95 | +4.9% | +5.7% | -7.1% | +9.3% | -3.4% | +0.7% |
| Nov 24 | D. Boral Capital | Downgrade | Buy → Hold | — | $0.90 | $1.60 | +78.4% | +13.7% | -3.9% | -8.2% | +7.8% | -5.2% |
| Oct 29 | D. Boral Capital | Maintains | Buy → Buy | — | $1.08 | $1.09 | +0.9% | -0.9% | -1.9% | +0.0% | +0.0% | -1.9% |
| Sep 26 | D. Boral Capital | Maintains | Buy → Buy | — | $1.03 | $1.03 | +0.0% | +0.0% | -1.9% | +3.0% | -1.0% | +1.0% |
| Sep 12 | D. Boral Capital | Maintains | Buy → Buy | — | $1.07 | $1.05 | -1.9% | +0.0% | +0.0% | +0.9% | -2.8% | +0.0% |
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.05 | $1.04 | -1.0% | +1.0% | +0.0% | +0.9% | -0.9% | -1.9% |
| Aug 22 | D. Boral Capital | Maintains | Buy → Buy | — | $1.03 | $1.01 | -1.9% | +1.9% | +2.9% | +0.0% | +0.9% | -4.6% |
| Aug 18 | D. Boral Capital | Maintains | Buy → Buy | — | $1.82 | $1.73 | -4.9% | -31.3% | -16.0% | +4.8% | -6.4% | +1.9% |
| Jul 29 | D. Boral Capital | Maintains | Buy → Buy | — | $1.26 | $1.30 | +3.2% | +12.7% | +8.5% | -3.2% | -2.7% | +2.1% |
| Jul 22 | D. Boral Capital | Maintains | Buy → Buy | — | $1.19 | $1.18 | -0.8% | -0.8% | -0.8% | -2.6% | -1.8% | +12.5% |
| Apr 21 | D. Boral Capital | Maintains | Buy → Buy | — | $0.86 | $0.86 | +0.1% | +2.3% | +1.1% | +3.4% | +4.3% | +2.6% |
| Apr 3 | D. Boral Capital | Maintains | Buy → Buy | — | $1.01 | $0.98 | -3.0% | -6.3% | -6.2% | +0.2% | +2.2% | +1.1% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.05 | $1.12 | +6.7% | -2.9% | +6.9% | -3.7% | -3.8% | +1.0% |
| Mar 3 | D. Boral Capital | Maintains | Buy → Buy | — | $1.20 | $1.03 | -14.2% | -15.0% | +5.9% | +4.6% | +1.8% | +3.5% |
| Feb 7 | D. Boral Capital | Maintains | Buy → Buy | — | $1.03 | $1.01 | -1.9% | +6.8% | -0.9% | -2.8% | -0.9% | -1.0% |
| Dec 11 | D. Boral Capital | Maintains | Buy → Buy | — | $1.25 | $1.25 | +0.0% | +0.8% | -4.0% | -0.8% | -3.3% | +1.7% |
| Dec 3 | D. Boral Capital | Maintains | Buy → Buy | — | $1.08 | $1.22 | +13.0% | +20.4% | +0.0% | -6.2% | +2.5% | +2.4% |
| Nov 14 | D. Boral Capital | Maintains | Buy → Buy | — | $1.18 | $1.16 | -1.7% | -8.5% | -0.9% | -1.9% | -1.9% | -5.2% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.58 | $1.59 | +0.6% | +3.8% | +2.4% | -4.2% | -3.7% | +1.9% |
| Sep 26 | EF Hutton | Maintains | Buy → Buy | — | $1.46 | $1.49 | +2.1% | +8.2% | +3.8% | +2.4% | -4.2% | -3.7% |
| Sep 24 | EF Hutton | Maintains | Buy → Buy | — | $1.48 | $1.50 | +1.4% | +0.0% | -1.4% | +8.2% | +3.8% | +2.4% |
| Sep 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.27 | $1.20 | -5.5% | -5.5% | +5.8% | +3.1% | +21.4% | -1.3% |
| Jun 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.36 | $1.38 | +1.5% | +4.4% | -2.1% | +6.5% | -1.4% | -4.8% |
| Apr 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.27 | $1.30 | +2.4% | +3.9% | +13.6% | -3.3% | -0.7% | +15.3% |
| Apr 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.83 | $1.89 | +3.3% | -13.7% | -17.7% | +11.5% | +2.1% | -5.4% |
| Sep 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.46 | $1.39 | -4.8% | +0.0% | +9.6% | +0.0% | -6.2% | +5.3% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.56 | $2.56 | +0.0% | +5.1% | -0.4% | +10.8% | -4.0% | -4.2% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.69 | $5.72 | +0.5% | -6.2% | -14.0% | -8.9% | -8.9% | +12.3% |
| Jun 16 | Roth Capital | Maintains | Buy → Buy | — | $269.60 | $284.00 | +5.3% | -6.5% | +2.5% | +7.4% | +1.6% | +3.5% |
| Jun 15 | Roth Capital | Maintains | Buy → Buy | — | $230.40 | $248.40 | +7.8% | +17.0% | -6.5% | +2.5% | +7.4% | +1.6% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Ark Investment Management Llc | 628,310 | $584K | New | Mar 2026 |
| 2 | Morgan Stanley | 401,254 | $282K | Added | Dec 2025 |
| 3 | Prelude Capital Management, Llc | 225,738 | $210K | New | Mar 2026 |
| 4 | Two Sigma Investments, Lp | 146,412 | $136K | Reduced | Mar 2026 |
| 5 | Ubs Group Ag | 138,328 | $129K | Added | Mar 2026 |
| 6 | Bank Of America Corp /de/ | 130,401 | $121K | Added | Mar 2026 |
| 7 | Renaissance Technologies Llc | 128,192 | $119K | Reduced | Mar 2026 |
| 8 | Jpmorgan Chase & Co | 125,948 | $113K | Added | Mar 2026 |
| 9 | Invesco Ltd. | 61,654 | $57K | Added | Mar 2026 |
| 10 | Jane Street Group, Llc | 74,082 | $52K | Added | Dec 2025 |
| 11 | Citadel Advisors Llc | 27,965 | $26K | Added | Mar 2026 |
| 12 | Millennium Management | 11,779 | $11K | New | Mar 2026 |
| 13 | Neuberger Berman Group Llc | 10,988 | $10K | — | Mar 2026 |
| 14 | Susquehanna International Group, Llp | 10,314 | $10K | New | Mar 2026 |
| 15 | Wells Fargo & Company/mn | 9,384 | $9K | New | Mar 2026 |
| 16 | Simplex Trading, Llc | 2,615 | $2K | Reduced | Mar 2026 |
| 17 | Mcguire Capital Advisors Inc | 2,500 | $2K | — | Mar 2026 |
| 18 | Arax Advisory Partners | 1,015 | $945 | — | Mar 2026 |
| 19 | Activest Wealth Management | 1,000 | $703 | — | Dec 2025 |
| 20 | Steward Partners Investment Advisory, Llc | 500 | $465 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | ARK Israel Innovative Technology ETF | 628,310 | $602K | Jan 2026 |
| 2 | Invesco NASDAQ Future Gen 200 ETF | 68,173 | $78K | Feb 2026 |
Valuation
Market Cap
$14.4M
Enterprise Value
$21.8M
P/E (TTM)
0.02x
Forward P/E
—
PEG Ratio
0.00x
P/B
0.01x
P/S
—
P/FCF
-2.64x
EV/EBITDA
—
Shares Out
48.5M
Financials (TTM)
Revenue
$0
Net Income
$1.24B
EBITDA
-$14.3M
Free Cash Flow
-$10.5M
Op Cash Flow
-$10.4M
EPS Basic
$27.04
EPS Diluted
$25.46
EPS Forward
$-0.08
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$2.33B
Total Liab.
$392.1M
Total Equity
$1.93B
Cash
$5.9M
LT Debt
$0
Book Value/Sh
$42.34
Debt/Equity
0.00x
Current Ratio
193.24
Quick Ratio
193.24
Returns & Growth
ROE
63.8%
ROA
53.1%
ROIC
-0.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
+3804.1%
Price Returns
2W
-20.7%
1M
-1.2%
3M
-29.5%
6M
-16.5%
12M
-13.4%
Technicals
52W High
$2.10
52W Low
$0.56
50d MA
$0.75
200d MA
$0.95
RSI (14)
22.10
ATR (14)
$0.06
Beta
1.68
Avg Volume
407K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$15.00
High
$15.00
Low
$15.00
Median
$15.00
Data updated apr 25, 2026 7:10am
· Source: financialmodelingprep.com